These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20392492)

  • 1. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
    Papageorgiou SG; Pappa V; Economopoulou C; Tsirigotis P; Konsioti F; Ionnidou ED; Chondropoulos S; Vasilatou D; Papageorgiou E; Economopoulos T; Dervenoulas J
    Leuk Res; 2010 Sep; 34(9):e254-6. PubMed ID: 20392492
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
    Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
    Sonmez M; Cobanoglu U; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
    Corm S; Renneville A; Rad-Quesnel E; Grardel N; Preudhomme C; Quesnel B
    Leukemia; 2007 Nov; 21(11):2376-7. PubMed ID: 17554376
    [No Abstract]   [Full Text] [Related]  

  • 5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
    Ault P
    Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
    Colla S; Sammarelli G; Crugnola M; Ascani S; Sabbatini E; Bonomini S; Hojden M; Craviotto L; De Celis I; Morandi F; Caramatti C; Rizzoli V; Giuliani N
    Eur J Haematol; 2004 May; 72(5):361-5. PubMed ID: 15059073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE; Sausen M; Joseph A; Kingham BF
    Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

  • 12. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
    Cherrier-De Wilde S; Rack K; Vannuffel P; Delannoy A; Hagemeijer A
    Leukemia; 2003 Oct; 17(10):2046-8. PubMed ID: 14513056
    [No Abstract]   [Full Text] [Related]  

  • 13. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
    Chen Y
    Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
    Bauer S; Romvari E
    Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
    Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
    Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
    Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
    Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
    Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
    Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
    Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
    Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
    Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.